ZYVERSA THERAPEUTICS, INC. Proceeds from Notes Payable
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Proceeds from Notes Payable of $719.08 thousand for the 6-month period ending 2021-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2022-11-14
- ZYVERSA THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2021-09-30 was $0.00.
- ZYVERSA THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2021-06-30 was $719.08K.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month |
|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | $719.08K 10-Q · filed 2022-11-14 |
| 2021-06-30 | $719.08K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |